Abstract
Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Letters in Drug Design & Discovery
Title: Schiff Bases of Istain: Antiglycation Activity
Volume: 6 Issue: 5
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Ambreen Khan, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Abstract: Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Ambreen Nida, Khan Ambreen, Perveen Shahnaz and Choudhary Iqbal Muhammad, Schiff Bases of Istain: Antiglycation Activity, Letters in Drug Design & Discovery 2009; 6 (5) . https://dx.doi.org/10.2174/1570180810906050358
DOI https://dx.doi.org/10.2174/1570180810906050358 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combination of Naringenin and Lisinopril Ameliorates Nephropathy in Type-1 Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Astrocytes: From the Physiology to the Disease
Current Alzheimer Research The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design The Impact of Oxidative Stress on Islet Transplantation and Monitoring the Graft Survival by Non-Invasive Imaging
Current Medicinal Chemistry Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry